Claims
- 1. A method of inducing apoptosis in a subject, comprising:
contacting an area of the subject with a nanocrystalline metal-containing compound to induce apoptosis at the area of the subject.
- 2. The method of claim 1, wherein the area of the subject is selected from the group consisting of a hyperplastic tissue, a tumor tissue and a cancer lesion.
- 3. The method of claim 1, wherein the method modulates matrix metalloproteinases at the area of the subject.
- 4. The method of claim 1, wherein the metal-containing compound is selected from the group consisting of metals and alloys.
- 5. The method of claim 1, wherein the metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.
- 6. The method of claim 1, wherein the metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.
- 7. The method of claim 1, wherein the metal-containing compound comprises silver.
- 8. The method of claim 1, wherein the metal-containing compound comprises an ionic compound.
- 9. The method of claim 1, wherein the metal-containing compound comprises atoms, molecules or clusters.
- 10. The method of claim 1, wherein the metal-containing compound comprises an atomically disordered, crystalline compound.
- 11. The method of claim 1, wherein the metal-containing compound comprises an antimicrobial compound.
- 12. The method of claim 1, wherein, when contacted with the area of the subject, the metal-containing compound is in a solution.
- 13. The method of claim 12, wherein the solution is injected.
- 14. The method of claim 13, wherein the solution is injected via a needleless injector.
- 15. The method of claim 12, wherein the solution is injected via a needle.
- 16. The method of claim 12, wherein the solution contains at least about 0.001 weight percent of the nanocrystalline metal-containing compound.
- 17. The method of claim 16, wherein the solution contains about 10 weight percent or less of the nanocrystalline metal-containing compound.
- 18. The method of claim 12, wherein the solution further comprises a solvent.
- 19. The method of claim 12, further comprising:
forming the solution into an aerosol; and inhaling the aerosol.
- 20. The method of claim 1, wherein, when contacted with the area of the subject, the nanocrystalline metal-containing compound is disposed in a pharmaceutically acceptable carrier.
- 21. The method of claim 20, wherein the composition contains at least about 0.01 weight percent of the nanocrystalline metal-containing compound.
- 22. The method of claim 21, wherein the composition contains about 50 weight percent or less of the nanocrystalline metal-containing compound.
- 23. The method of claim 20, wherein the pharmaceutically acceptable carrier is selected from the group consisting of creams, ointments, gels, lotions, pastes and foams.
- 24. The method of claim 1, wherein, when contacted with the area of the subject, the nanocrystalline metal-containing compound is in the form of a free-standing powder.
- 25. The method of claim 24, wherein the free-standing powder is inhaled.
- 26. The method of claim 24, wherein the free-standing powder is injected.
- 27. A method of modulating matrix metalloproteinases in a subject, comprising:
contacting an area of the subject with a nanocrystalline metal-containing compound to modulate matrix metalloproteinases at the area of the subject.
- 28. The method of claim 27, wherein the area is selected from the group consisting of a hyperplastic tissue, a tumor tissue and a cancer lesion.
- 29. The method of claim 27, wherein the metal-containing compound is selected from the group consisting of metals and alloys.
- 30. The method of claim 27, wherein the metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.
- 31. The method of claim 27, wherein the metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.
- 32. The method of claim 27, wherein the metal-containing compound comprises silver.
- 33. The method of claim 27, wherein the metal-containing compound comprises an ionic compound.
- 34. The method of claim 27, wherein the metal-containing compound comprises atoms, molecules or clusters.
- 35. The method of claim 27, wherein the metal-containing compound comprises a disordered, crystalline compound.
- 36. The method of claim 27, wherein the metal-containing compound comprises an antimicrobial compound.
- 37. The method of claim 27, wherein, when contacted with the area of the subject, the metal-containing compound is in a solution.
- 38. The method of claim 37, wherein the solution is injected.
- 39. The method of claim 38, wherein the solution is injected via a needleless injector.
- 40. The method of claim 38, wherein the solution is injected via a needle.
- 41. The method of claim 37, wherein the solution contains at least about 0.001 weight percent of the nanocrystalline metal-containing compound.
- 42. The method of claim 41, wherein the solution contains about 10 weight percent or less of the nanocrystalline metal-containing compound.
- 43. The method of claim 37, wherein the solution further comprises a solvent.
- 44. The method of claim 37, further comprising:
forming the solution into an aerosol; and inhaling the aerosol.
- 45. The method of claim 27, wherein, when contacted with the area of the subject, the metal-containing compound is disposed in a pharmaceutically acceptable carrier.
- 46. The method of claim 45, wherein the composition contains at least about 0.01 weight percent of the metal-containing compound.
- 47. The method of claim 46, wherein the composition contains about 50 weight percent or less of the metal-containing compound.
- 48. The method of claim 45, wherein the pharmaceutically acceptable carrier is selected from the group consisting of creams, ointments, gels, lotions, pastes and foams.
- 49. The method of claim 27, wherein, when contacted with the area of the subject, the nanocrystalline metal-containing compound is in the form of a free-standing powder.
- 50. The method of claim 49, wherein the free-standing powder is inhaled.
- 51. The method of claim 49, wherein the free-standing powder is injected.
- 52. A method of inducing apoptosis in a subject, comprising:
contacting an area of the subject with an atomically disordered, crystalline metal-containing compound to induce apoptosis at the area of the subject.
- 53. The method of claim 52, wherein the area is selected from the group consisting of a hyperplastic tissue, a tumor tissue and a cancer lesion.
- 54. The method of claim 52, wherein the method modulates matrix metalloproteinases at the area of the subject.
- 55. The method of claim 52, wherein the metal-containing compound is selected from the group consisting of metals and alloys.
- 56. The method of claim 52, wherein the metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.
- 57. The method of claim 52, wherein the metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.
- 58. The method of claim 52, wherein the metal-containing compound comprises silver.
- 59. The method of claim 52, wherein the metal-containing compound comprises an ionic compound.
- 60. The method of claim 52, wherein the metal-containing compound comprises atoms, molecules or clusters.
- 61. The method of claim 52, wherein the metal-containing compound comprises an antimicrobial compound.
- 62. A method of modulating matrix metalloproteinases in a subject, comprising:
contacting an area of the subject with an atomically disordered, crystalline metal-containing compound to modulate matrix metalloproteinases at the area of the subject.
- 63. The method of claim 62, wherein the area is selected from the group consisting of a hyperplastic tissue, a tumor tissue and a cancer lesion.
- 64. The method of claim 62, wherein the metal-containing compound is selected from the group consisting of metals and alloys.
- 65. The method of claim 62, wherein the metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.
- 66. The method of claim 62, wherein the metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.
- 67. The method of claim 62, wherein the metal-containing compound comprises silver.
- 68. The method of claim 62, wherein the metal-containing compound comprises an ionic compound.
- 69. The method of claim 62, wherein the metal-containing compound comprises atoms, molecules or clusters.
- 70. The method of claim 62, wherein the metal-containing compound comprises an antimicrobial compound.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part and claims the benefit of priority under 35 U.S.C. §120 of: U.S. patent application Ser. No. 09/628,735, filed Jul. 27, 2000, and entitled “Treatment of Hyperproliferative Skin Disorders and Diseases;” U.S. patent application Ser. No. 09/916,757, filed Jul. 27, 2001, and entitled “Treatment of Hyperproliferative Skin Disorders and Diseases;” U.S. patent application Ser. No. 09/840,637, filed Apr. 23, 2001, and entitled “Treatment of Acne;” U.S. Provisional Patent Application Serial No. 60/285,884, filed Apr. 23, 2001, and entitled “Therapeutic Treatments Using the Direct Application of Noble Metal Compositions;” U.S. patent application Ser. No. 10/131,512, filed Apr. 23, 2002, and entitled “Therapeutic Treatments Using the Direct Application of Noble Metal Compositions;” U.S. patent application Ser. No. 10/131,509, filed Apr. 23, 2002, and entitled “Treatment of Mucosal Membranes;” U.S. patent application Ser. No. 10/131,511, filed Apr. 23, 2002, and entitled “Treatment of Inflammatory Skin Conditions;” U.S. patent application Ser. No. 10/131,568, filed Apr. 23, 2002, and entitled “Method of Induction of Apoptosis and Inhibition of Matrix Metalloproteinases Using Antimicrobial Metals;” and U.S. patent application Ser. No. 10/159,587, filed May 30, 2002, and entitled “Method of Induction of Apoptosis and Inhibition of Matrix Metalloproteinases Using Antimicrobial Metals.” Each of these applications is incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60285884 |
Apr 2001 |
US |
Continuation in Parts (8)
|
Number |
Date |
Country |
Parent |
09628735 |
Jul 2000 |
US |
Child |
10277320 |
Oct 2002 |
US |
Parent |
09916757 |
Jul 2001 |
US |
Child |
10277320 |
Oct 2002 |
US |
Parent |
09840637 |
Apr 2001 |
US |
Child |
10277320 |
Oct 2002 |
US |
Parent |
10128208 |
Apr 2002 |
US |
Child |
10277320 |
Oct 2002 |
US |
Parent |
10131509 |
Apr 2002 |
US |
Child |
10277320 |
Oct 2002 |
US |
Parent |
10131511 |
Apr 2002 |
US |
Child |
10277320 |
Oct 2002 |
US |
Parent |
10131568 |
Apr 2002 |
US |
Child |
10277320 |
Oct 2002 |
US |
Parent |
10159587 |
May 2002 |
US |
Child |
10277320 |
Oct 2002 |
US |